At a glance
This program funds investigator-initiated studies on how GLP-1 or dual GLP-1/GIP-1 receptor agonists affect cancer risk, with a focus on mechanisms and related cancer biomarkers or cancer endpoints. It accepts new and resubmission applications, and clinical trials are optional. Eligible applicants include U.S. and non-U.S. organizations, including nonprofits, universities, governments, small businesses, and faith-based or community-based organizations. There is no cost sharing requirement, the award amount is not limited, the project period can be up to 5 years, and the number of awards depends on NIH funding and meritorious applications.
What it funds
Official description from grants.gov
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments